Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Cell. Neurosci., 24 November 2025

Sec. Cellular Neuropathology

Volume 19 - 2025 | https://doi.org/10.3389/fncel.2025.1739705

Correction: CRISPR-Cas9: bridging the gap between aging mechanisms and therapeutic advances in neurodegenerative disorders

This article is a correction to:

  1. CRISPR-Cas9: bridging the gap between aging mechanisms and therapeutic advances in neurodegenerative disorders

    1. Read original article
Anas ShamsiAnas Shamsi1Mohammed Alrouji Mohammed Alrouji2*Othman AlOmeirOthman AlOmeir3Syed TasqeruddinSyed Tasqeruddin4Khuzin DinislamKhuzin Dinislam5Azna Zuberi Azna Zuberi6*
  • 1Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates
  • 2Department of Medical Laboratories, College of Applied Medical Sciences, Shaqra University, Shaqra, Saudi Arabia
  • 3Department of Clinical Pharmacy, College of Pharmacy, Shaqra University, Shaqra, Saudi Arabia
  • 4Department of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University, Abha, Saudi Arabia
  • 5Department of General Chemistry, Bashkir State Medical University, Ufa, Russia
  • 6Department of Obstetrics and Gynecology, Northwestern University, Chicago, IL, United States

A Correction on
CRISPR-Cas9: bridging the gap between aging mechanisms and therapeutic advances in neurodegenerative disorders

by Shamsi, A., Alrouji, M., AlOmeir, O., Tasqeruddin, S., Dinislam, K., and Zuberi, A. (2025). Front. Cell. Neuroscience. 19:1681891. doi: 10.3389/fncel.2025.1681891

In the published article, in the author list, the fifth author's name was erroneously spelled as “Khzuin Dinislam” instead of the correctly spelt version “Khuzin Dinislam”.

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: CRISPR-Cas9, gene editing, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), aging

Citation: Shamsi A, Alrouji M, AlOmeir O, Tasqeruddin S, Dinislam K and Zuberi A (2025) Correction: CRISPR-Cas9: bridging the gap between aging mechanisms and therapeutic advances in neurodegenerative disorders. Front. Cell. Neurosci. 19:1739705. doi: 10.3389/fncel.2025.1739705

Received: 05 November 2025; Revised: 09 November 2025;
Accepted: 10 November 2025; Published: 24 November 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Shamsi, Alrouji, AlOmeir, Tasqeruddin, Dinislam and Zuberi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Azna Zuberi, YXpuYS56dWJlcmlAbm9ydGh3ZXN0ZXJuLmVkdQ==; Mohammed Alrouji, bWFscm91amlAc3UuZWR1LnNh

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.